Publication | Open Access

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapyOncologyRadiation OncologyRefractory Multiple MyelomaHealth Sciences